CXCL12 and prostate cancer: Consistent with our data, KPT-330 has been shown to inhibit SDF1-mediated signalling, preventing the migration of CLL cells34, and to restrict tumour spreading and the metastasis of prostate cancer cells by decreasing the secretion of metalloproteinases and urokinase35.